Diana Mckenzie - 01 May 2026 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Reporting relationship: Director
Issuer ticker: VRTX
Reported as of: 01 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 May 2026, 17:18:16 UTC
Prior SEC filing: 03 Apr 2026
Next SEC filing: 04 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Christiana Stevenson, Attorney-in-Fact

Key filing fact

Diana Mckenzie filed Form 4 for VERTEX PHARMACEUTICALS INC / MA (VRTX) on 05 May 2026.

Key facts

This page summarizes Diana Mckenzie's Form 4 filing for VERTEX PHARMACEUTICALS INC / MA (VRTX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 May 2026, 17:18.

Change

Previous filing in this sequence was filed on 03 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001754648 Primary reporting owner

MCKENZIE DIANA

Relationship: Director
Address: C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON
Signature: /s/ Christiana Stevenson, Attorney-in-Fact
Signature date: 05 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VRTX transaction

Common Stock

Award

Transaction value
Shares: +943
Change %: +42%
Price: $0.000000^*
Shares after: 3,174
Date: 01 May 2026
Ownership: Direct
Footnotes: F1

VRTX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -796
Change %: -25%
Price
Shares after: 2,378
Date: 01 May 2026
Ownership: Direct
Footnotes: F2

VRTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 207
Date: 01 May 2026
Ownership: Held in Trust

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VRTX transaction Derivative

Deferred Stock Units

Award

Transaction value
Shares: +796
Change %: +11%
Price
Shares after: 7,787
Date: 01 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 796
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Restricted stock unit award that vests, subject to certain limited exceptions, on the first anniversary of the grant date.

Footnote F2

Upon the vesting of restricted stock units granted to Ms. McKenzie on May 1, 2025, Ms. McKenzie deferred the receipt of 796 shares of common stock and received instead 796 deferred stock units pursuant to our deferred compensation plan. As a result, Ms. McKenzie is reporting the disposition of 796 shares of common stock in exchange for an equal number of deferred stock units.

Footnote F3

Each deferred stock unit represents one share of common stock and is paid out in common stock upon the earliest to occur of (i) termination of Ms. McKenzie's service on our board of directors, (ii) a change of control of our company and (iii) Ms. McKenzie's disability or death.